NCT03375021View on ClinicalTrials.gov

CX717 in the Treatment of Adult ADHD

PHASE2CompletedINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

July 19, 2005

Primary Completion Date

January 10, 2006

Study Completion Date

January 10, 2006

Conditions
Attention Deficit Hyperactivity Disorder
Interventions
DRUG

CX717 200 mg

CX717 200 mg capsules BID

DRUG

CX717 800 mg

CX717 4 X 200 mg capsules BID

DRUG

Placebo

Placebo 200 mg or 800 mg capsules BID

All Listed Sponsors
lead

RespireRx

INDUSTRY

NCT03375021 - CX717 in the Treatment of Adult ADHD | Biotech Hunter | Biotech Hunter